THThalia Herrera-Calvo

Thalia Herrera-Calvo

*This is an algorithmically generated author record based on publicly available information.

Thalia Herrera-Calvo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved

    by Alberto Polo-Barranco, Carlos Rebolledo-Maldonado, Dairo Rodelo-Barrios, Juan Solano-Ropero, Valentina Rada-Obeso, Carlos Lavalle-Jiménez, Valeria Blanchar-Martínez, Carlos Beltran-Sánchez, Augusto Maza-Arnedo, Thalia Herrera-Calvo, et al.

    Elevated plasma lipoprotein(a) [Lp(a)] levels represent a predominantly genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease (CAVD). Mechanistically, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcific remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, recruitment of cells of the monocytic lineage, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin–lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells toward myofibroblastic and/or osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence supports an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.

  • Open Access

    Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved

    by Alberto Polo-Barranco, Carlos Rebolledo-Maldonado, Dairo Rodelo-Barrios, Juan Solano-Ropero, Valentina Rada-Obeso, Carlos Lavalle-Jiménez, Valeria Blanchar-Martínez, Carlos Beltran-Sánchez, Augusto Maza-Arnedo, Thalia Herrera-Calvo, et al.

    Lipoprotein(a) [Lp(a)] is a predominantly genetic risk factor for atherosclerotic cardiovascular disease and calcified aortic valve disease (CAVD). In addition to its epidemiological and genetic association with aortic stenosis, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcifying remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, monocyte and macrophage recruitment, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin-lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells to myofibroblastic and osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence support an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.